Strengths

Kura Oncology maintains a strong liquidity position with a current ratio of 4.73 and cash per share of 5.84.

Gross profit margin remains very high at 94.7%, indicating strong product-level economics.

Debt remains modest relative to market value, with debt-to-assets at 4.2% and debt-to-equity at 0.50.

Weaknesses

Profitability remains deeply negative, with net profit margin at -384.3% and ROE at -207.2%.

Operating cash flow is still negative at -$1.26 per share, and free cash flow per share is -$1.32.

Operating leverage remains unfavorable, with SG&A at 174.7% of revenue and R&D at 336.0% of revenue.

Opportunities

The company’s high gross margin provides room for operating leverage if revenue scales.

A strong cash position supports continued pipeline investment and clinical development.

Valuation metrics such as price-to-sales and EV-to-sales remain elevated, implying upside depends on execution rather than multiple expansion.

Threats

Persistent losses and negative cash flow create ongoing financing and dilution risk.

High R&D and SG&A intensity may continue to pressure margins if commercialization lags.

The stock remains priced for growth, with price-to-sales at 12.48 and EV-to-sales at 11.89, leaving limited room for disappointment.

Overall Score